Recent preclinical or clinical studies suggested that the strategies of blocking anti-phagocytic CD47/SIRPα interaction to enable macrophages phagocytosis of tumor cells showed promise in cancer therapy.31 32Here, our results provided the evidence about the overexpression of CD47 in human colorectal tumor tissues compared with the matched normal tissues, and the increased CD47 expression negatively correlated with overall survival, which indicated poor clinical outcomes. The gene discussed is CD47; the disease is cancer.